Long-Acting ART With Cabotegravir And Rilpivirine Superior To Oral ART Therapy Among Patients With HIV, Data Indicate

Infectious Disease Advisor (4/15, Nye) reports, “Interim results from a randomized trial indicate that long-acting antiretroviral therapy (ART) with cabotegravir and rilpivirine is superior to oral ART among patients with HIV infection who are unable to maintain virologic suppression on daily oral regimens.” In February, “an independent Data and Safety Monitoring Board (DSMB) conducted a preplanned review of interim data and found that long-acting ART with cabotegravir and rilpivirine was superior to daily oral ART.” The results were announced in an NIH press release.